GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (NAS:CARA) » Definitions » Cash Flow from Investing
中文

Cara Therapeutics (Cara Therapeutics) Cash Flow from Investing : $43.46 Mil (TTM As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Cara Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Cara Therapeutics spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $65.00 Mil on purchasing investments. It gained $36.85 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $2.05 Mil for other investing activities. In all, Cara Therapeutics spent $30.21 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Cara Therapeutics Cash Flow from Investing Historical Data

The historical data trend for Cara Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics Cash Flow from Investing Chart

Cara Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -30.52 -20.28 -4.75 128.71 43.46

Cara Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.42 17.71 32.80 23.16 -30.21

Cara Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Cara Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Cara Therapeutics's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $43.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cara Therapeutics  (NAS:CARA) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Cara Therapeutics's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Cara Therapeutics spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Cara Therapeutics's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Cara Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Cara Therapeutics's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Cara Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Cara Therapeutics's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Cara Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Cara Therapeutics's purchase of investment for the three months ended in Dec. 2023 was $-65.00 Mil. It means Cara Therapeutics spent {stock_data.stock.currency_symbol}}65.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Cara Therapeutics's sale of investment for the three months ended in Dec. 2023 was $36.85 Mil. It means Cara Therapeutics gained $36.85 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Cara Therapeutics's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Cara Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Cara Therapeutics's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Cara Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Cara Therapeutics's cash from other investing activities for the three months ended in Dec. 2023 was $-2.05 Mil. It means Cara Therapeutics paid $2.05 Mil for other investing activities.


Cara Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Cara Therapeutics (Cara Therapeutics) Business Description

Traded in Other Exchanges
Address
107 Elm Street, 9th Floor, 4 Stamford Plaza, Stamford, CT, USA, 06902
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Executives
Christopher Posner director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Helen M Boudreau director 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Joana Goncalves officer: Chief Medical Officer C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Scott Terrillion officer: Sec'y; Chief Compliance & G.C. C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Menzaghi Frederique Ph.d. officer: VP-Research & Development C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Moltke Lisa Von director C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Martin Vogelbaum director 675 ALMANOR AVE, SUNNYVALE CA 94085
Ryan D Maynard officer: Chief Financial Officer RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Csl Ltd 10 percent owner
Jeffrey L. Ives director C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Bains Harrison M Jr director
Thomas Charles Reilly officer: Chief Financial Officer C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Vifor Fresenius Medical Care Renal Pharma Ltd. 10 percent owner RECHENSTRASSE 37, CH-9014, ST. GALLEN V8 9014
Vifor (international) Ltd 10 percent owner RECHENSTRASSE 37, ST. GALLEN V8 9000
Vifor Pharma Ltd. 10 percent owner UNTERMATTWEG 8, BERNE V8 CH-3027